Allo Bank and Bank Mega Lead Historic Syndicated Loan for Plasma Fractionation Facility

Supporting National Health Security

PT Allo Bank Indonesia Tbk (BBHI) and PT Bank Mega Tbk (MEGA), both part of CT Corp, have successfully led a Rp3.7 trillion syndicated loan for PT SKPlasma Core Indonesia. This groundbreaking financing supports the development of Indonesia's first plasma fractionation facility, strategically located in Karawang, West Java ¹

Key Features of the Project

1. First Domestic Plasma Fractionation: The facility will be Indonesia's first to manufacture plasma-derived products, reducing the country's reliance on imported medical supplies
2. Strategic Health Investment: The project represents a long-term investment in national health security and self-sufficiency
3. Critical Product Manufacturing: The facility will produce essential plasma-derived products including immunoglobulin and albumin therapies
4. Economic Impact: The project is expected to create significant employment opportunities and stimulate local economic development

Industry Context and Future Prospects

The plasma fractionation facility addresses a critical gap in Indonesia's healthcare infrastructure. Currently, the country is heavily dependent on imported plasma-derived products. By developing domestic manufacturing capacity, Indonesia can improve supply chain resilience and ensure better access to essential medical treatments ²

Chief Wholesale and Treasury of Allo Bank, Yogi Bima Sakti, emphasized that this financing demonstrates the bank's commitment to supporting strategic healthcare projects with long-term national benefits. The facility is expected to become a cornerstone of Indonesia's healthcare ecosystem, ensuring the availability of high-quality plasma-derived products ¹